Spin-Off Research Slashes Mural Oncology Valuation [Forbes]
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: Forbes
immunotherapies, provided an update on the Phase 3 ARTISTRY-7 trial of Nemvaleukin in combination with KEYTRUDA® (pembrolizumab) in patients with Platinum-Resistant Ovarian Cancer (PROC). Based on overall survival data observed in the interim analysis, Mural halted the phase 3 ovarian cancer trial involving nemvaleukin alfa. (for more information, visit spinoffresearch.com). Given the setback, the market reacted negatively, and the stock nosedived ~71%. However, Nemvaleukin will continue to be evaluated in a potentially registrational phase 2 trial, ARTISTRY-6, cohort 2, in mucosal melanoma. The topline data readout is expected in 2Q25. Moreover, the preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma are expected in 2Q25 for cohort 3 of ARTISTRY-6 (monotherapy) and in 2H25 for cohort 4 of ARTISTRY-6 (combination therapy), subject to patient enrolment. Earlier in 4Q24, the Company expanded its pipeline by nominating two d
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc [Yahoo! Finance]Yahoo! Finance
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionGlobeNewswire
- Mural Oncology Announces Sanction of the Scheme by the High CourtGlobeNewswire
- Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyGlobeNewswire
MURA
Sec Filings
- 12/5/25 - Form S-8
- 12/5/25 - Form S-8
- 12/5/25 - Form S-8
- MURA's page on the SEC website